The future leaves
signals in time.

Scientists discovered a rare mutation that protects the brain from harmful protein buildup, allowing some individuals with a high genetic risk of Alzheimer's to remain mentally sharp into their 80s. These findings suggest a potential new way to prevent early brain damage and could pave the way for treatments that mimic this natural defense.

Scientists identified overactive immune cells in the brain as an unexpected culprit behind sleep loss in Alzheimer's disease. Temporarily removing these cells restored more than two hours of sleep per day in mice, suggesting a possible new treatment target; this is animal-model research, not yet shown in humans.

According to mid-stage study results reported Monday, an oral treatment from Gilead Sciences eliminated symptoms experienced by patients with a type of inflammatory bowel disease. The findings come from a mid-stage study.

Mayo Clinic researchers have found that fatty liver disease, which affects nearly 30% of adults worldwide, actually consists of five distinct biological subtypes, each carrying different risks for liver failure, cancer, heart disease, and other serious complications.

A Nature Medicine article title concerns molecular predictors of minimal residual disease in newly diagnosed multiple myeloma patients treated with quadruplet therapy. No further details are provided in the available context, so specific findings cannot be confirmed.

Scientists found that a protein linked to youth helps protect the brain's immune cells from age-related decline. Restoring the protein in older mice improved the cells' debris-clearing ability and reduced signs of inflammation, raising hopes for future treatments targeting brain aging and Alzheimer's disease; the evidence so far comes from mouse studies.

Scientists report that a potential new drug reversed severe fatty liver disease in animal models by restoring gut health and blocking harmful substances from reaching the liver. They say the finding could pave the way for new treatments for liver disease and potentially other serious conditions, including cardiovascular disease; the evidence so far comes from animal models.

Stanford scientists have developed a new microscope that reveals the inner workings of living cells in real time without the fluorescent labels that can interfere with observations. The breakthrough could provide new insights into cancer, infectious diseases and how drugs interact with cells.

According to STAT, following a green light from the FDA, European regulators have now recommended approval of Revolution Medicines' (RevMed) pancreatic cancer drug Rasonque, moving the drug closer to European approval.

University of Southern California (USC) scientists report a way to create a potentially renewable supply of genetically engineered immune cells that can attack cancer and strengthen the body's natural defenses. By growing and modifying immature immune cells rather than mature ones, the researchers developed a system that can continuously produce tumor-fighting cells inside the body.

Researchers found that activating the PPARD protein in immune cells made them better at burning fat and attacking tumors, slowing or stopping cancer growth in laboratory experiments. The approach showed promise against colorectal, breast, and ovarian cancers, as well as melanoma.

Scientists identified a mechanism in which the gene DEAF1 becomes overactive with age and interferes with muscles' ability to clear damaged proteins and repair themselves. Exercise can help restore this balance, allowing older muscles to rebuild and regain strength, though the benefits may diminish when the system becomes too disrupted.

Nature Medicine published a phase 1 trial of an EGFR-targeted antibody-toxin conjugate in recurrent glioma. The feed provides no further details; results and conclusions are as reported in the original article.

Nature Medicine published a study on real-world, digital-first delivery of GLP-1 receptor agonist therapy in women. The feed provides no further details; specific findings are as reported in the original article.

Speaking at the STAT Summit, Moderna's Stephen Hoge and Merck's Dean Li said the companies will pair Keytruda with personalized mRNA vaccines to target tumors, and that after initial success there is a 'lot of exploring to do.' The provided context does not include specific efficacy data.

Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which is being studied in more than 200 patients with advanced solid tumors, including metastatic pancreatic ductal adenocarcinoma. The reported findings remain early-stage.

A schoolteacher diagnosed with melanoma gives a first-person account of being treated with an mRNA cancer vaccine developed by Merck and Moderna. The report is framed around the patient's experience, with the headline saying the vaccine delivered hope and a path forward.